Portal de investigación
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Reck, Martin
- Ciuleanu, Tudor-Eliade
- Cobo, Manuel
- Schenker, Michael
- Zurawski, Bogdan
- de Menezes, Juliana Janoski
- Richardet, Eduardo
- Felip, Jaafar Bennouna Enriqueta
- Alexandru, Aurella
- Sakai, Hiroshi
- Scherpereel, Arnaud
- Lu, Shun
- Paz-Ares, Luis G.
- Carbone, David Paul
- Memaj, Arteid
- Marimuthu, Sathiya
- Phuong Tran
- John, Tom
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0732-183X, 1527-7755
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 9,378 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF CLINICAL ONCOLOGY AMER SOC CLINICAL ONCOLOGY
Citas Recibidas en Web of Science: 15
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Reck,M,Ciuleanu,T,Cobo,M,Schenker,M,Zurawski,B,de Menezes,JJ,Richardet,E et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA:AMER SOC CLINICAL ONCOLOGY. 2021.